RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2024 | 04/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.44% | 20.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.44% | 20.55% | |||
| Cost of Revenue | -25.14% | 9.66% | |||
| Gross Profit | 61.69% | 51.19% | |||
| SG&A Expenses | -25.01% | 24.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -31.82% | 1.54% | |||
| Total Operating Expenses | -25.06% | 20.40% | |||
| Operating Income | 43.55% | -20.29% | |||
| Income Before Tax | 43.21% | 24.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.21% | 24.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.21% | 24.72% | |||
| EBIT | 43.55% | -20.29% | |||
| EBITDA | 50.30% | -24.61% | |||
| EPS Basic | 42.99% | 24.65% | |||
| Normalized Basic EPS | 43.28% | 24.72% | |||
| EPS Diluted | 42.99% | 24.65% | |||
| Normalized Diluted EPS | 43.28% | 24.72% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
